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Summary The cellular content of receptors for epidermal growth factor (EGF) was measured in different
histological subgroups of human mammary carcinomas. EGF receptors were detected in 36% of the ductal
and all the medullary carcinomas. In contrast lobular and pure colloid tumours did not contain measurable
amounts of the receptor.
The receptor was found both among tumours with an euploid and aneuploid DNA pattern. The EGF
receptor is thus found in carcinomas with a varying degree of differentiation as judged by the cellular DNA
pattern. There was no correlation between the proliferative activity of the tumours as measured by
thymidinekinase activity and the amount of EGF receptors in the tumour.
Tumours with detectable EGF receptor often had low levels of oestrogen receptor. This finding could only
partly be explained by the menstrual status of the patients.
Epidermal growth factor (EGF) has been shown to
stimulate in vitro growth of epithelial cells derived
both from normal breast and mammary carcinomas
(Fitzpatrick et al., 1984). A prerequisite for the
growth promoting effect of EGF seems to be the
presence of a cellular receptor for EGF (Heldin &
Westermark, 1984). Plasma membrane receptors
have been found in approximately 40% of biopsies
from human breast carcinomas (Perez et al., 1984;
Fitzpatrick et al., 1984). The amount of EGF
bound varied between 1-121 fmolmg-1 membrane
protein (Fitzpatrick et al., 1984). The significance of
cellular EGF receptor content with respect to
tumour cell differentiation and growth is at present
obscure. However there seems to be an inverse
relationship between the receptors for EGF and
oestrogen (Peirez et al., 1984; Fitzpatrick et al.,
1984). Since high levels of oestrogen receptors are
found in well differentiated breast carcinomas
(Erhardt et al. to be published) it is tempting to
speculate that detectable levels of the EGF receptor
are confined to poorly differentiated carcinomas.
The activity of thymidine kinase-1 (Tk-1) has
been found to increase when cells enter the S phase
(Adler & McAuslan, 1974). Analysis of this enzyme
would thus reflect the proliferative rate in a
tumour. To our knowledge there are no reports
concerning the activity of Tk-1 in breast cancer.
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The present study was undertaken to evaluate if
there exists a relationship between the cellular EGF
receptor content and degree of differentiation as
measured by morphological criteria, DNA ploidy
and hormone receptors.
Material and methods
Tumour specimens
All specimens were collected from fresh surgical
resections and stored at -80°C until analyzed for
receptor content, thymidine kinase and DNA
pattern. A total of 37 primary carcinomas was
analyzed for receptor content and DNA pattern.
No preoperative treatment had been given to the
patients. The series included 17 premenopausal and
20 postmenopausal women.
Tumour cytosol and membrane fractions were
prepared from -1 g tumour tissue. After
homogenization in 5 ml of buffer (5mM NaPO4,
pH7.4, 1 mm DTT and 10% glycerol) using a
Polytron with intermittent bursts of 15 sec each, an
aliquot was withdrawn for measurements of total
DNA using the method of Burton (1956). The
homogenate was then centrifuged at 100,000g for
40min at 0°C. The resulting supernatant was used
for ER analysis and thymidine kinase deter-
mination. The pellet was resuspended in 1Omm Tris
HCl, pH 7.4, the suspension was recentrifuged at
100,000g for 60min at 0°C and the resulting pellet
was used for EGF receptor binding.
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Histological classification
The classification proposed by McDivitt et al.
(1969) was used. From over 300 cases of primary
breast carcinomas only pure forms of each subclass
were selected and further analyzed.
ER assay
The cytosol receptor for oestradiol was measured as
described by Wrange et al. (1969).
Thymidine kinase assay
The two isoenzymes of TdR-kinase were separated
by isoelectric focusing of tumour cell cytosol in
slabs of 1.1% agarose (10). The enzyme focusing
around pH8.5 (IP8.5) was determined by cutting
out the section of the gel between pH8.7-8.2. This
piece was incubated in 1.8ml of 80mm Tris-HCl,
pH8.0, containing 5mM ATP, 5mM MgCl2, 6mM
glycerol-3-phosphate and 0.08 mm of [3H]-labelled
TdR (specific activity 1 Cimmol-1). After
incubation at 37°C for 12h the reaction was
stopped by boiling for 90 sec and cooled on ice. The
supernatant formed after centrifugation at 3,000g
for 10min was used for determination of dTMP
formed by paper chromatography (MacNutt, 1952).
EGF receptor determination
The receptor concentration in the individual breast
tumours was carried out using a series of 7 samples.
Each sample contained membrane proteins
(>100 Mg), 125I-EGF (-100,000cpm) unlabelled
EGF (varying between 0-0.5jg) in 0.5ml of
binding buffer (10mM Tris-HCl, pH7.4, 10mm
MgCl2 and 0.1% (w/v) BSA). Incubation was
carried out at 20°C for 1 h. The binding was
stopped by the addition of 10vol ice cold binding
buffer. After centrifugation at 3,000g for 30min at
0°C the resulting pellet was resuspended in 1 M
NaOH and the radioactivity measured. Specific
high affinity binding was calculated by subtracting
non-specific binding in the presence of 500ng cold
EGF from total binding and the data were
calculated according to the procedure of Scatchard
(1969). The nonspecific binding was in the order of
2-3% of the total counts. The cellular content of
the EGF receptor was expressed as amol bound
1g-' DNA. Placental tissue was used as a positive
control. The variation between assays of the control
never exceeded 8%.
DNA pattern analysis
Single cell DNA measurements were performed on
imprint specimens from thawed tumour material.
These specimens were fixed, hydrolyzed and stained
with acriflavine-SO2, and the DNA quantitation
was made in a Leitz MPV3 cytophotometer. The
technical details of preparation and analysis have
*been described previously (Bjelkenkrantz, 1983). In
each sample more than 150 tumour cell nuclei were
selected and their DNA content measured.
Histograms showing the distribution of DNA
content in the cells were constructed for each case,
as suggested by Auer et al. (1980). Differences in
tumour aggressiveness were small in between types
I/II and types III/IV, therefore, in the present study
only two groups were distinguished. Euploid
tumours consisting of cases where the DNA histo-
grams show a distinct peak at the normal diploid
or at the tetraploid DNA value, or both, with only
a few cells outside the range of these peaks.
Aneuploid tumours consisting of cases with a
sizeable number of cells outside the diploid-tetra-
ploid peaks, or cases that show an irregular or
aneuploid distribution of DNA in the nuclei.
Statistical analysis
The Chi-square test was used.
Material sources
Mouse epidermal growth factor (EGF) was
isolated from mouse submaxillary glands as
described by Savage & Cohen (1972). EGF was
iodinated by the chloramine T method (Hunter &
Greenwood, 1962). 125Iodine was purchased from
Amersham, England. Ampholines and PAGE plates
were obtained from LKB, Sweden. [3H]-oestradiol
(151 Cimmol-1) and [3H]-TdR (42Cimmol-1)
were provided by NEN, Germany and Amersham,
UK, respectively.
Results
Characteristics ofthe EGFbinding
The binding of [125II-labelled EGF to crude
membrane fractions from human mammary
carcinomas reached saturation within 40min at
20°C. Scatchard analysis of [125I]-EGF binding
revealed two binding sites for EGF one of which is
a high affinity site with an average dissociation
constant of 2 x 10-9 M. This finding is in good
agreement with other studies on human breast
cancer (Perez et al., 1984; Fitzpatrick et al., 1984).
The results presented for EGF-R determination
refer only to high affinity binding. Figure 1 shows
that 3 euploid and 7 aneuploid tumours had
detectable levels of the EGF receptor. This
difference did not reach statistical significance
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Figure 1 The distribution of ER and EGF-R in euploid and aneuploid tumours, respectively. Tumours were
obtained from premenopausal (0) and postmenopausal ( x ) subjects.
The EGF-R values ranged between 0 to
80amol-P1 g DNA and only one tumour had a
value over 50amol g1- I DNA.
EGF-R in different histological subclasses
The most common subclass of human mammary
carcinomas is that of the ductal type. Analysis of
[125I]-EGF binding to 22 tumours of this subtype is
presented in Table I. This table shows that 8 had
high affinity binding sites for the growth factor
while 14 had no detectable receptors.
Carcinomas of the classical medullary type are
found infrequently and only 2 cases were available
for analysis. Both tumours had high affinity
receptors for EGF (Table I).
Two sub-groups, pure colloid and lobular car-
cinomas, did not contain any measurable EGF-R.
Fibroadenomas are benign tumours of lobular
origin. Three such tumours were analyzed for EGF-
R and all three were found to be negative (Table I).
Table I The EGF-R in different subclasses of
mammary carcinomas and fibroadenomas
Histologic EGF-R
subtype detectable/total
Ductal 8/22
Lobular 0/9
Medullar 2/2
Colloid 0/4
Fibroadenomas 0/3
EGF-R content and DNA pattern
The DNA pattern of mammary carcinomas has
been suggested to reflect cellular differentiation
(Olszewski et al., 1981). Thus euploid tumours are
considered to represent well differentiated
carcinomas with a less aggressive behaviour. In
contrast aneuploid tumours are regarded as poorly
differentiated which tend to be more aggressive
than the euploid tumours. It was therefore of
interest to study the relationship between the ploidy
of the tumours and their content of EGF-R
In the group of 22 ductal carcinomas 6 were
euploid and of these 2 had high affinity receptors
for EGF. Among the aneuploid tumours 6 were
positive while 11 were negative for EGF-R (Figure 2).
The two medullary carcinomas were both
aneuploid and contained detectable levels of
EGF-R.
Among the lobular carcinomas 5 were euploid
and 4 aneuploid. However, as previously described
all these tumours were negative for EGF binding
(Figure 2).
All three fibroadenomas were euploid and lacked
the EGF-R (data not shown).
Receptorsfor oestradiol and EGF
It has previously been described that EGF-R
containing tumours often had a low cellular content
of oestradiol receptors (ER) (Perez et al., 1984;
Fitzpatrick et al., 1984). As can be seen from
Figure I all but one tumour with detectable EGF-R
had ER levels below 0.4fmolHg-1 DNA (P<0.05).
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Figure 2 The distribution of EGF-R in euploid and
aneuploid tumours, respectively. Unfilled bars repre-
sent EGF-R positive tumours. Hatched bars represent
non-detectable levels of EGF-R in lobular carcinomas
(vertical hatching) and ductal, colloid and papillary
carcinomas (horizontal hatching).
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Figure 3 Thymidine kinase
negative and positive tumours.
activity in EGF-R
However of these 10 tumours 6 were obtained from
premenopausal women, who in general have lower
ER than postmenopausal women.
Only 1 tumour with EGF-R had a high ER
content, 4.8 fmolpg-1 DNA. This tumour was a
highly differentiated ductal carcinoma of papillary
type.
Thymidine kinase activity and EGF-R
The cellular level of the thymidine kinase isoenzyme
with an IP of 8.5 has been found to be increased
in cells engaged in DNA synthesis (Adler &
McAuslan, 1974; Nordenskjold et al., 1970). It
therefore seems likely that measurements of this
enzyme will give an estimate of the proliferative
activity of the tumours. It was therefore considered
of interest to study the level of this enzyme in
human mammary carcinomas with respect to
EGF-R. The results from analysis of 37 carci-
nomas are depicted in Figure 3 which shows that
there was no correlation between the cellular
content of thymidine kinase and EGF-R. No
correlation was found between thymidine kinase
activity and morphological subtype.
Thymidine kinase and DNA pattern
Mammary carcinomas with an euploid DNA
pattern have been suggested to represent a group of
tumours with a low growth rate as compared to
that of aneuploid carcinomas (Erhardt et al., to be
published). We therefore analyzed the relation
between thymidine kinase and DNA pattern in the
37 different mammary carcinomas described above
plus 10 others. Figure 4 shows that the cellular
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Figure 4 Relationship between thymidine kinase acti-
vity and tumour ploidy. The filled circles represent
individual tumours while the triangles denote the mean
value of enzyme activity in each group.
levels of thymidine kinase were significantly higher
(P=0.05) in the aneuploid tumours that in the
euploid ones. Thus the mean value for euploid
tumours was 6.4pmolpg-1 DNA as compared to
14.6pmolpg-1 DNA in the aneuploid group.
However, there was a considerable overlap between
the thymidine kinase values in the two groups.
Discussion
EGF has been shown to have a mitogenic effect on
breast cancer cells in vitro (Fitzpatrick et al., 1984).
It is widely accepted that EGF exerts this effect via
membrane receptors on the cell (Heldin &
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Westermark, 1984). The presence of this receptor
has been demonstrated both in breast cancer cells
grown in vitro and in biopsies from human
mammary carcinomas. Approximately 40% of the
tumour biopsies have detectable receptors for EGF
(Perez et al., 1984; Fitzpatrick et al., 1984). It is not
known if the frequency of EGF-R positivity is the
same in all histological subgroups of human
mammary carcinomas. To analyze this we selected
from a large number of tumours typical cases for
each subgroup. Our results show that 36% of
ductal carcinomas have high affinity binding sites
for EGF with -60-600 sites per cell. Since ductal
carcinomas represent 80-85% of all breast cancers
our figure agrees with that for an unselected
material of breast carcinomas (Perez et al., 1984).
The absence of EGF-R in lobular carcinomas is
of interest. We have previously reported that
lobular carcinomas differ from ductal carcinomas
with respect to cellular content of ER and receptors
for vitamin A (Skoog et al., 1985). Thus ductal and
lobular carcinomas appear to have different
capacities for regulation by several growth factors
as EGF, vitamin A and oestradiol.
Colloid carcinomas also lacked EGF-R. It is
suggested that colloid carcinomas represent a highly
differentiated ductal tumour. It is tempting to
speculate that the low degree of malignancy which
is a hall-mark of colloid cancers may in some way
be related to the absence of EGF-R (Silverberg et
al., 1971). However, the number of tumours studied
is small and our data should be interpreted
cautiously.
The absence of detectable levels of EGF-R in
fibroadenomas may seem puzzling for two reasons.
First, primary cultures of fibroadenomas are
induced to proliferate by EGF (Stoker et al., 1976).
Second, fibroblasts in tissue culture have detectable
EGF-R. However, it is possible that this
discrepancy may result from the comparison of an
in vivo with an in vivo situation with different levels
of EGF-R expression. The affinity for EGF in
fibroblasts seems to be comparatively low, which
may also contribute to our results (Sainsbury et al.,
1985).
In line with reports by others we found that cells
with measurable EGF-R tended to have a low level
of cytoplasmic ER (Perez et al., 1984; Fitzpatrick et
al., 1984; Sainsbury et al., 1985). In the present
material this finding could be partly explained by
the fact that approximately 50% of these tumours
were obtained from premenopausal women. It is
well documented that premenopausal women have
low ER in their tumours since endogenously
produced oestradiol will block the receptor (Theve
et al., 1978).
The absence of detectable EGF-R in some
tumours can be explained in several ways. In the
first place as a result of transformation EGF-R
expression is induced or increased in tumour cells.
This mechanism has been suggested for gliomas but
does not appear to be a general phenomenon
(Libermann et al., 1984; Cherington et al., 1979;
Hollenberg et al., 1979). Secondly, some tumours
might be exposed to endogenous EGF or related
peptides such as TGF-a which then leads to a
masking/down regulation of the receptor (Heldin &
Westermark, 1984). A third possibility is that
expression of EGF-R is present in all normal cells
and that this phenotype sometimes is lost as a
result of malignant transformation. In the latter
case one would assume that poorly differentiated
carcinomas should lack EGF-R more often. This
does not seem to be the case since in our study
EGF-R was present in both euploid and aneuploid
tumours albeit in slightly different proportions.
We were also unable to find any correlation
between EGF-R levels and the proliferative activity
as measured by cellular content of thymidine kinase
isoenzyme with p18.5. This isoenzyme increases in
S phase and thus correlates with the proportion
of cells synthesizing DNA (Adler & McAuslan,
1974; Nordenskjdld et al., 1970). The expression of
EGF-R does not seem to be the result of a
low/high growth rate in the tumours. Moreover this
lack of correlation between receptor and prolifera-
tive activity also seems to rule out the possibility that
the low levels of EGF-R result from an endogenous
binding of mitogenic growth factors. The difference
in EGF-R levels between morphological subgroups
might therefore represent true biological differences.
The clinical relevance of such a difference remains
to be elucidated.
A second finding of interest is that the activity of
thymidine kinase tended to be higher in tumours
with an aneuploid DNA pattern as compared to
those with an euploid pattern. This is in line with
the proposed high proliferative activity in aneuploid
tumours (Bjelkenkrantz et al., to be published). The
relevance of this observation with respect to tumour
aggressiveness and clinical course of the disease
needs to be further studied.
In conclusion, our data suggest that EGF-R
positivity is confined only to certain subgroups of
mammary carcinomas. This finding is of interest
when considering growth regulation of mammary
tumours as well as the possible use of EGF-R as a
prognostic indicator.
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